In vivo study of a polymeric glucose-sensitive insulin delivery system using a rat model

Journal of Pharmaceutical Sciences

Volumn 99, Issue 10, 2010, Pages 4215-4227

  Taylor, M Joan ^a   Sangeeta, Tanna ^a   Tarsem, Sahota ^a  

^a DE MONTFORT UNIVERSITY   (United Kingdom)

Author keywords

Closed loop; Concanavalin A; Dextran methacrylate; Diabetes; Glucose sensitive; Implantable insulin devices; Insulin; Peritoneal

Indexed keywords

ACRYLIC ACID; DEXTRAN; GLUCOSE; NEUTRAL INSULIN; POLYMER;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DEVICE; DRUG DELIVERY SYSTEM; EQUIPMENT DESIGN; GEL; GLUCOSE BLOOD LEVEL; IMPLANT; NONHUMAN; PERFORMANCE; RAT;

EID: 77957354612     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22138     Document Type: Article

References (39)

1. Panteleon AE, Loutseiko M, Steil GM, Rebrin K. 2006. Evaluation of the effect of gain on the meal response of an automated closed-loop insulin delivery system. Diabetes 55:1995-2000. (Pubitemid 44509972)
2. Renard E. 2002. Implantable closed-loop glucose-sensing and insulin delivery: The future for insulin pump therapy. Curr Opin Pharmacol 2:708-716.
3. Saudek C. 1993. Future developments in insulin delivery systems. Diabetes Care 16:122-132.
4. Anon. 2002. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. J Am Med Assoc 287:2563-2569.
5. Anon. 1996. Lifetime benefits and costs of intensive therapy as practised in the diabetes control and complications trial. J Am Med Assoc 276:1409-1415.
6. DeFronzo RA. 1999. Implications of the United Kingdom prospective diabetes study. Prim Care 26:809-827.
7. Ahmed N. 2005. Advanced glycation endproducts - Role in pathology of diabetic complications. Diabetes Res Clin Pract 67:3-21.
8. Anon. 2008. Diabetes. Beware the silent assassin, 1st edition. London: Diabetes UK.
9. Figueroa-Romero C, Sadidi M, Feldman EL. 2008. Mechanisms of disease: The oxidative stress theory of diabetic neuropathy. Rev Endocr Metab Disord 9:301-314.
10. Home P. 2003. The challenge of poorly controlled diabetes mellitus. Diabetes Metab 29:101-109.
11. Kingdom A, Ferguson B. 2006. Diabetes key facts (YHPHO), 1st edition. United Kingdom: Yorkshire and Humber Public Health Observatory.
12. Shah BR, Hux JE, Laupacis A, Zinman B, van Walraven C. 2005. Clinical inertia in response to inadequate glycemic control: Do specialists differ from primary care physicians? Diabetes Care 28:600-606.
13. Vinik A. 2007. Advancing therapy in type 2 diabetes mellitus with early, comprehensive progression from oral agents to insulin therapy. Clin Ther 29:1236-1253.
14. Farmer TG, Jr., Edgar TF, Peppas NA. 2008. The future of open- and closed-loop insulin delivery systems. J Pharm Pharmacol 60:1-13.
15. Hovorka R. 2006. Continuous glucose monitoring and closed-loop systems. Diabetes Med 23:1-12.
16. Hovorka R, Kremen J, Blaha J, Matias M, Anderlova K, Bosanska L, Roubicek T, Wilinska ME, Chassin LJ, Svacina S, Haluzik M. 2007. Blood glucose control by a model predictive control algorithm with variable sampling rate versus a routine glucose management protocol in cardiac surgery patients: A randomized controlled trial. J Clin Endocrinol Metab 92:2960-2964.
17. Kizilel S, Garfinkel M, Opara E. 2005. The bioartificial pancreas: Progress and challenges. Diabetes Technol Ther 7:968-985.
18. Renard E. 2008. Clinical experience with an implanted closed-loop insulin delivery system. Arq Bras Endocrinol Metabol 52:349-354.
19. Renard E, Costalat G, Chevassus H, Bringer J. 2006. Closed loop insulin delivery using implanted insulin pumps and sensors in type 1 diabetic patients. Diabetes Res Clin Pract 74:S173-S177.
20. Renard E, Costalat G, Chevassus H, Bringer J. 2006. Artificial beta-cell: Clinical experience toward an implantable closed-loop insulin delivery system. Diabetes Metab 32:497-502.
21. Renard E, Schaepelynck-Belicar P. 2007. Implantable insulin pumps. A position statement about their clinical use. Diabetes Metab 33:158-166.
22. Young TH, Chuang WY, Hsieh MY, Chen LW, Hsu JP. 2002. Assessment and modeling of poly(vinyl alcohol) bioartificial pancreas in vivo. Biomaterials 23:3495-3501.
23. Selam JL. 2001. External and implantable insulin pumps: Current place in the treatment of diabetes. Exp Clin Endocrinol Diabet 109:S333-S340.
24. Selam JL. 2006. CSII in Europe: Where are we, where are we going? An analysis of articles published in Infusystems International. Diabetes Res Clin Pract 74:S123-S126.
25. Pickup JC, Renard E. 2008. Long-acting insulin analogs versus insulin pump therapy for the treatment of type 1 and type 2 diabetes. Diabetes Care 31:S140-S145.
26. Edelman SV. 2007. Intensive insulin therapy in type 2 diabetes. Insulin 2:S34-S40.
27. Weinzimer SA, Steil GM, Swan KL, Dziura J, Kurtz N, Tamborlane WV. 2008. Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care 31:934-939.
28. Steil G, Rebrin K, Mastrototaro JJ. 2006. Metabolic modelling and the closed-loop insulin delivery problem. Diabetes Res Clin Pract 74:S183-S186.
29. Heller A, Feldman B. 2008. Electrochemical glucose sensors and their applications in diabetes management. Chem Rev 108:2482-2505.
30. Rubin J, Reed V, Adair C, Bower J, Klein E. 1986. Effect of intraperitoneal insulin on solute kinetics in CAPD: Insulin kinetics in CAPD. Am J Med Sci 291:81-87.
31. Selam JL, Bergman RN, Raccah D, Jean-Didier N, Lozano J, Charles MA. 1990. Determination of portal insulin absorption from peritoneum via novel nonisotopic method. Diabetes 39:1361-1365.
32. Wideroe TE, Dahl KJ, Smeby LC, Balstad T, Cruischank-Flakne S, Folling I, Simondsen O, Ahlmen J, Jorstad S. 1996. Pharmacokinetics of transperitoneal insulin transport. Nephron 74:283-290.
33. Edgerton DS, Lautz M, Scott M, Everett CA, Stettler KM, Neal DW, Chu CA, Cherrington AD. 2006. Insulin's direct effects on the liver dominate the control of hepatic glucose production. J Clin Invest 116:521-527.
34. Girard J. 2006. Insulin's effect on the liver: "Direct or indirect?" continues to be the question. J Clin Invest 116:302-304.
35. Velho G, Froguel P, Reach G. 1989. Determination of peritoneal glucose kinetics in rats: Implications for the peritoneal implantation of closed-loop insulin delivery systems. Diabetologia 32:331-336.
36. Tanna S, Taylor MJ, Sahota TS, Sawicka K. 2006. Glucose-responsive UV polymerised dextran-concanavalin A acrylic derivatised mixtures for closed-loop insulin delivery. Biomaterials 27:1586-1597.
37. Tanna S, Sahota TS, Sawicka K, Taylor MJ. 2006. The effect of degree of acrylic derivatisation on dextran and concanavalin A glucose-responsive materials for closed-loop insulin delivery. Biomaterials 27:4498-4507.
38. Mason TM, Gupta N, Goh T, El-Bahrani B, Zannis J, van de Werve G, Giacca A. 2000. Chronic intraperitoneal insulin delivery, as compared with subcutaneous delivery, improves hepatic glucose metabolism in streptozotocin diabetic rats. Metabolism 49:1411-1416.
39. Kwon DS, Gao X, Liu YB, Dulchavsky DS, Danyluk AL, Bansal M, Chopp M, McIntosh K, Arbab AS, Dulchavsky SA, Gautam SC. 2008. Treatment with bone marrow-derived stromal cells accelerates wound healing in diabetic rats. Int Wound J 5:453-463.